UBS Group’s InspireMD, Inc. Series B Warrants NSPRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-20,620
| Closed | -$2K | – | 11501 |
|
|
2021
Q4 | $2K | Buy |
20,620
+17,462
| +553% | +$1.82K | ﹤0.01% | 9933 |
|
|
2021
Q3 | $0 | Sell |
3,158
-34,049
| -92% | -$4.84K | ﹤0.01% | 10582 |
|
|
2021
Q2 | $7K | Sell |
37,207
-85,341
| -70% | -$5.66K | ﹤0.01% | 8401 |
|
|
2021
Q1 | $5K | Sell |
122,548
-67,045
| -35% | -$3.18K | ﹤0.01% | 8372 |
|
|
2020
Q4 | $3K | Buy |
189,593
+88,493
| +88% | +$1.13K | ﹤0.01% | 8054 |
|
|
2020
Q3 | $1K | Hold |
101,100
| – | – | ﹤0.01% | 7890 |
|
|
2020
Q2 | $2K | Hold |
101,100
| – | – | ﹤0.01% | 7699 |
|
|
2020
Q1 | $1K | Hold |
101,100
| – | – | ﹤0.01% | 7861 |
|
|
2019
Q4 | $0 | Hold |
101,100
| – | – | ﹤0.01% | 8565 |
|
|
2019
Q3 | $1K | Hold |
101,100
| – | – | ﹤0.01% | 7888 |
|
|
2019
Q2 | $1K | Hold |
101,100
| – | – | ﹤0.01% | 7767 |
|
|
2019
Q1 | $0 | Buy |
101,100
+1,100
| +1% | +$1 | ﹤0.01% | 8370 |
|
|
2018
Q4 | $0 | Sell |
100,000
-47,696
| -32% | -$129 | ﹤0.01% | 8444 |
|
|
2018
Q3 | $1K | Buy |
147,696
+141,648
| +2,342% | +$1.27K | ﹤0.01% | 7882 |
|
|
2018
Q2 | $0 | Hold |
6,048
| – | – | ﹤0.01% | 8369 |
|
|
2018
Q1 | $0 | Sell |
6,048
-200
| -3% | -$6 | ﹤0.01% | 8315 |
|
|
2017
Q4 | $0 | Buy |
6,248
+100
| +2% | +$3 | ﹤0.01% | 8213 |
|
|
2017
Q3 | $0 | Buy |
+6,148
| New | +$524 | ﹤0.01% | 8112 |
|
UBS Group's NSPRZ Position: Q1 2022 in Review
UBS Group sold out of InspireMD, Inc. Series B Warrants (NSPRZ) in Q1 2022, closing a stake of 20,620 shares — an estimated $2K sold.
UBS Group first reported a position in NSPRZ in Q3 2017 and held it in 18 quarters. The position peaked at $7K in Q2 2021. 0 funds tracked by Wall St. Rank hold NSPRZ as of Q1 2022.
- UBS Group reported no remaining InspireMD, Inc. Series B Warrants position as of Q1 2022 after selling out during the quarter.
- UBS Group sold 20,620 InspireMD, Inc. Series B Warrants shares in Q1 2022, an estimated $2K.
- UBS Group first reported a position in InspireMD, Inc. Series B Warrants in Q3 2017 and held it in 18 quarters.
- UBS Group's InspireMD, Inc. Series B Warrants position peaked at $7K in Q2 2021.
- 0 funds tracked by Wall St. Rank held InspireMD, Inc. Series B Warrants as of Q1 2022.
Based on UBS Group's 13F filing for Q1 2022, filed 16 May 2022.